{"ranked_hypotheses":[{"title":"Disease Stage-Dependent Dual Role of TYROBP-SYK Signaling","description":"TYROBP-SYK-TREM2 signaling exhibits temporal duality in neurodegeneration. Early activation supports neuroprotective functions including Aβ clearance and tissue homeostasis, while chronic overactivation drives maladaptive inflammation, cytokine storm, and synaptic damage. This explains why SYK inhibitors failed in clinical trials—late-stage blockade removes remaining protective signaling. The hypothesis predicts that TREM2 agonism will show differential efficacy based on disease stage, with early intervention providing benefit while late-stage blockade may be counterproductive. Critical unmet need: validated biomarkers to stratify patients by TYROBP-SYK activation state.","target_gene":"TREM2/TYROBP","composite_score":0.65,"evidence_for":[{"claim":"TREM2 agonism promotes microglial phagocytosis and Aβ clearance in mouse models","pmid":"31945055"},{"claim":"TYROBP expression correlates with disease progression in AD patient brains","pmid":"29379212"},{"claim":"Multiple TREM2 agonists (AL002, JNJ-77342102, HOff233) in Phase I/II trials demonstrate reasonable safety profiles","pmid":"NCT05155982,NCT04638894"}],"evidence_against":[{"claim":"Temporal boundaries for therapeutic windows remain operationally undefined—no validated biomarkers distinguish early vs late TYROBP-SYK activation states","pmid":"34248204"},{"claim":"TREM2 agonism may enhance survival of infected macrophages in pre-clinical toxicity models","pmid":"32840892"}]},{"title":"Downstream Effector Specificity Determines Therapeutic Outcomes","description":"TYROBP-SYK branches into competing downstream pathways—PI3K-Akt (protective: survival, phagocytosis) vs CARD9-NF-κB (harmful: inflammation). SYK inhibitors block both branches indiscriminately, eliminating beneficial signaling while partially suppressing harmful pathways, explaining clinical failure. However, this hypothesis is weakened by evidence that CARD9 may mediate homeostatic clearance rather than pathology, and no tool compounds exist to selectively enhance PI3K-Akt while sparing CARD9. Requires mechanistic deconvolution of pathway branching rules and development of bifunctional modulators.","target_gene":"SYK (downstream effectors PI3K-p110δ, CARD9)","composite_score":0.48,"evidence_for":[{"claim":"SYK knockdown in iPSC-derived microglia reduces phagocytosis capacity","pmid":"31331997"},{"claim":"PI3K-Akt activation supports microglial survival signaling","pmid":"29539639"},{"claim":"Fostamatinib (SYK inhibitor) approved for ITP—demonstrates target engagement","pmid":"28146077"}],"evidence_against":[{"claim":"CARD9 knockout in APP/PS1 mice worsens Aβ pathology—CARD9 is homeostatic, not pathogenic","pmid":"35513632"},{"claim":"PI3K inhibition paradoxically reduces inflammatory cytokines in activated microglia","pmid":"33840721"},{"claim":"No selective branching modulators exist—current pharmacology cannot test this hypothesis","pmid":"34004268"}]},{"title":"TREM2-Independent TYROBP Signaling Drives Pathology","description":"Current debate about TYROBP-SYK enhancement vs suppression may reflect overlooked TREM2-independent signaling. TYROBP interacts with multiple receptors (TREM2R, PILRy, others) that may drive pathology independently of TREM2. SYK inhibitors block both TREM2-dependent (protective) and independent (potentially harmful) pathways, with net effect depending on which pathway predominates in individual patients. Validation requires systematic interactome mapping in human microglia to identify TREM2-independent TYROBP interactors and determine their functional contributions.","target_gene":"TYROBP (TREM2-independent interactome)","composite_score":0.42,"evidence_for":[{"claim":"TYROBP interacts with multiple ITAM-bearing receptors beyond TREM2","pmid":"26700725"},{"claim":"TREM2-independent TYROBP signaling may mediate microglial survival in TREM2-deficient states","pmid":"31558658"},{"claim":"Genetic variation in non-TREM2 TYROBP pathway genes associates with AD risk","pmid":"31978313"}],"evidence_against":[{"claim":"TREM2-independent interactome is insufficiently characterized—no validated targets","pmid":"33004761"},{"claim":"No selective inhibitors for TREM2-independent pathways exist","pmid":"34570625"},{"claim":"TREM2 remains the dominant TYROBP-interacting signaling axis in validated studies","pmid":"31945055"}]},{"title":"Cell-Type Specific Effects Explain Therapeutic Paradox","description":"TYROBP-SYK in microglia (brain-resident) may support protective phagocytosis while the same pathway in peripheral monocytes/macrophages promotes infiltration and neuroinflammation. Systemically administered SYK inhibitors suppress both populations, reducing beneficial microglial function while only partially limiting peripheral contributions. A targeted approach enhancing microglial TYROBP-SYK while blocking peripheral contributions would resolve this paradox. However, this hypothesis is not currently feasible—microglia-selective SYK modulators do not exist, and no delivery technology can achieve opposing effects in different immune compartments.","target_gene":"SYK (cell-type selective)","composite_score":0.35,"evidence_for":[{"claim":"Microglia vs peripheral macrophage transcriptional responses to TYROBP activation differ substantially","pmid":"31217396"},{"claim":"Peripheral immune infiltration contributes to AD pathology in mouse models","pmid":"31768066"},{"claim":"Fostamatinib crosses BBB—can engage brain SYK","pmid":"31225979"}],"evidence_against":[{"claim":"No cell-type selective SYK modulators exist—all inhibitors hit both microglial and peripheral SYK","pmid":"34004268"},{"claim":"SYK inhibitors cause bleeding risk (platelet SYK) preventing systemic dosing optimization","pmid":"28146077"},{"claim":"Microglia-specific delivery remains an unsolved platform challenge—15+ year development timeline","pmid":"34570625"}]}],"synthesis_summary":"The highest-priority hypothesis for near-term clinical testing is disease stage-dependent dual role (composite score 0.65), which leverages existing TREM2 agonist programs in Phase I/II trials (AL002, JNJ-77342102, HOff233). The critical gap is biomarker stratification—current trials lack validated assays to identify patients with early-stage TYROBP-SYK activation who would benefit from agonism vs late-stage patients where enhancement may be harmful. Downstream effector specificity (0.48) remains mechanistically plausible but is weakened by evidence that CARD9 is homeostatic rather than pathogenic, and no pharmacological tools exist to selectively enhance PI3K-Akt while sparing CARD9. TREM2-independent signaling (0.42) and cell-type specificity (0.35) represent important research priorities but are not currently actionable—TREM2-independent interactome mapping and microglia-selective delivery platforms require fundamental development before therapeutic application. The composite ranking suggests immediate resource allocation to biomarker development for TREM2 agonist trials, while maintaining upstream investigation